Phase I Study of SHR7390 in Patients With Advanced Solid Tumors
Status:
Unknown status
Trial end date:
2019-07-01
Target enrollment:
Participant gender:
Summary
This aim of study to assess the safety and tolerability of SHR7390 and to define the maximum
tolerated dose (MTD) of SHR7390 in the patients with advanced solid tumors.
To evaluate the pharmacokinetics of SHR7390 in patients with advanced solid tumors.
To study the effects of food on the pharmacokinetic parameters of SHR7390. To assess the
antitumor activity of SHR7390 in patients with advanced solid tumors preliminarily and
recommend reasonable dosage regimen for the follow-up clinical trial.